Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.
Biotech Investors: August’s Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.
Morgan Stanley Maintains Overweight on BeiGene, Lowers Price Target to $293
Morgan Stanley analyst Matthew Harrison maintains BeiGene (NASDAQ:BGNE) with a Overweight and lowers the price target from $300 to $293.
Beigene’s Inspections Delay Suggest Eventual Approval, Says This Analyst
Beigene Limited (NASDAQ: BGNE) provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell carcinoma (ESCC).
U.S. FDA Defers Decision On BeiGene’s Filing For Esophageal Carcinoma Due To Pending Inspection
The U.S. Food and Drug Administration (FDA) has deferred decision on the Biologics License Application (BLA) for BeiGene’s (NASDAQ: BGNE) tislelizumab as a second-line treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC).
BeiGene Provides Regulatory Update On The U.S. Biologics License Application For PD-1 Inhibitor Tislelizumab In 2L ESCC
FDA Defers Action on BLA Until Required Inspections Can Be Completed
Due to COVID Travel Restrictions, Inspections Could Not Be Completed During Review Period
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
BeiGene Announces BRUKINSA Is Approved In 50 Markets
BeiGene and NewBridge Pharmaceuticals To Bring BRUKINSA to Patients in MENA Region, Following Approval for Previously Treated Mantle Cell Lymphoma in Kuwait, Bahrain and Qatar
BRUKINSA has Previously Been Approved by
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways:
Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule
The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year’s first-quarter
52 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247 million.